Skip to main content
Top
Published in: Infectious Agents and Cancer 1/2010

Open Access 01-12-2010 | Methodology

Ultrasensitive quantitation of human papillomavirus type 16 E6 oncogene sequences by nested real time PCR

Authors: Socorro Hernández-Arteaga, Rubén López-Revilla

Published in: Infectious Agents and Cancer | Issue 1/2010

Login to get access

Abstract

Background

We have developed an ultrasensitive method based on conventional PCR preamplification followed by nested amplification through real time PCR (qPCR) in the presence of the DNA intercalating agent EvaGreen.

Results

Amplification mixtures calibrated with a known number of pHV101 copies carrying a 645 base pair (bp)-long insert of the human papillomavirus type 16 (HPV16) E6 oncogene were used to generate the E6-1 amplicon of 645 bp by conventional PCR and then the E6-2 amplicon of 237 bp by nested qPCR. Direct and nested qPCR mixtures for E6-2 amplification corresponding to 2.5 × 102-2.5 × 106 initial pHV101 copies had threshold cycle (Ct) values in the ranges of 18.7-29.0 and 10.0-25.0, respectively. The Ct of qPCR mixtures prepared with 1/50 volumes of preamplified mixtures containing 50 ng of DNA of the SiHa cell line (derived from an invasive cervical cancer with one HPV16 genome per cell) was 19.9. Thermal fluorescence extinction profiles of E6-2 amplicons generated from pHV101 and SiHa DNA were identical, with a peak at 85.5°C.

Conclusions

Our method based on conventional preamplification for 15 cycles increased 10,750 times the sensitivity of nested qPCR for the quantitation of the E6 viral oncogene and confirmed that the SiHa cell line contains one E6-HPV16 copy per cell.
Appendix
Available only for authorised users
Literature
1.
go back to reference Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348 (6): 518-527. 10.1056/NEJMoa021641.PubMedCrossRef Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348 (6): 518-527. 10.1056/NEJMoa021641.PubMedCrossRef
2.
go back to reference Bosch FX: Epidemiology of human papillomavirus infections: new options for cervical cancer prevention. Salud Publica Mex. 2003, 45 (Suppl 3): S326-339.PubMed Bosch FX: Epidemiology of human papillomavirus infections: new options for cervical cancer prevention. Salud Publica Mex. 2003, 45 (Suppl 3): S326-339.PubMed
3.
go back to reference Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189 (1): 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.PubMedCrossRef Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189 (1): 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.PubMedCrossRef
4.
go back to reference Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME, Bratti MC, Rodriguez AC, Helzlsouer KJ, Schiffman M: A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev. 2003, 12 (6): 477-484.PubMed Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME, Bratti MC, Rodriguez AC, Helzlsouer KJ, Schiffman M: A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev. 2003, 12 (6): 477-484.PubMed
5.
go back to reference Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, Vollmer N, Menton S, Menton M, Dietz K, Wallwiener D, et al: Detection and typing of human papillomavirus by e6 nested multiplex PCR. J Clin Microbiol. 2004, 42 (7): 3176-3184. 10.1128/JCM.42.7.3176-3184.2004.PubMedPubMedCentralCrossRef Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, Vollmer N, Menton S, Menton M, Dietz K, Wallwiener D, et al: Detection and typing of human papillomavirus by e6 nested multiplex PCR. J Clin Microbiol. 2004, 42 (7): 3176-3184. 10.1128/JCM.42.7.3176-3184.2004.PubMedPubMedCentralCrossRef
6.
go back to reference Hubbard RA: Human papillomavirus testing methods. Arch Pathol Lab Med. 2003, 127 (8): 940-945.PubMed Hubbard RA: Human papillomavirus testing methods. Arch Pathol Lab Med. 2003, 127 (8): 940-945.PubMed
7.
go back to reference Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007, 357 (16): 1579-1588. 10.1056/NEJMoa071430.PubMedCrossRef Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007, 357 (16): 1579-1588. 10.1056/NEJMoa071430.PubMedCrossRef
8.
go back to reference Noda T, Sasagawa T, Dong Y, Fuse H, Namiki M, Inoue M: Detection of human papillomavirus (HPV) DNA in archival specimens of benign prostatic hyperplasia and prostatic cancer using a highly sensitive nested PCR method. Urol Res. 1998, 26 (3): 165-169. 10.1007/s002400050041.PubMedCrossRef Noda T, Sasagawa T, Dong Y, Fuse H, Namiki M, Inoue M: Detection of human papillomavirus (HPV) DNA in archival specimens of benign prostatic hyperplasia and prostatic cancer using a highly sensitive nested PCR method. Urol Res. 1998, 26 (3): 165-169. 10.1007/s002400050041.PubMedCrossRef
9.
go back to reference Lopez-Revilla R, Martinez-Contreras LA, Sanchez-Garza M: Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma. Infect Agent Cancer. 2008, 3: 3-10.1186/1750-9378-3-3.PubMedPubMedCentralCrossRef Lopez-Revilla R, Martinez-Contreras LA, Sanchez-Garza M: Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma. Infect Agent Cancer. 2008, 3: 3-10.1186/1750-9378-3-3.PubMedPubMedCentralCrossRef
10.
go back to reference Hernandez-Arteaga S, Lopez-Revilla R: Quantitation of human papillomavirus type 16 E6 oncogene sequences by real-time or quantitative PCR with EvaGreen. Anal Biochem. 2008, 380 (1): 131-133. 10.1016/j.ab.2008.05.012.PubMedCrossRef Hernandez-Arteaga S, Lopez-Revilla R: Quantitation of human papillomavirus type 16 E6 oncogene sequences by real-time or quantitative PCR with EvaGreen. Anal Biochem. 2008, 380 (1): 131-133. 10.1016/j.ab.2008.05.012.PubMedCrossRef
11.
go back to reference Friedl F, Kimura I, Osato T, Ito Y: Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc Soc Exp Biol Med. 1970, 135 (2): 543-545.PubMedCrossRef Friedl F, Kimura I, Osato T, Ito Y: Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc Soc Exp Biol Med. 1970, 135 (2): 543-545.PubMedCrossRef
12.
go back to reference Brody JR, Kern SE: Sodium boric acid: a Tris-free, cooler conductive medium for DNA electrophoresis. Biotechniques. 2004, 36 (2): 214-216.PubMed Brody JR, Kern SE: Sodium boric acid: a Tris-free, cooler conductive medium for DNA electrophoresis. Biotechniques. 2004, 36 (2): 214-216.PubMed
Metadata
Title
Ultrasensitive quantitation of human papillomavirus type 16 E6 oncogene sequences by nested real time PCR
Authors
Socorro Hernández-Arteaga
Rubén López-Revilla
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue 1/2010
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/1750-9378-5-9

Other articles of this Issue 1/2010

Infectious Agents and Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine